R Sen - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

R Sen

Showing results (271-280 of 274) with videos related to

Pageof 28

Sort By:

You have reached the last page of results.This site can display upto 274 results.

Biorxiv : the Preprint Server for Biology|February 26, 2024

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapyOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.

Cell Reports. Medicine|June 27, 2025

Overcoming resistance to immunotherapy by targeting CD38 in human tumor explantsOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.

Nature|January 12, 2023

Targeting TBK1 to overcome resistance to cancer immunotherapyYi Sun, Or-Yam Revach, Seth Anderson, et al.

Nature|October 4, 2023

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunityChristina K Baumgartner, Hakimeh Ebrahimi-Nik, Arvin Iracheta-Vellve, et al.

Pageof 28

Search research articles

Showing results (271-280 of 274) with videos related to

Sort By:

Pageof 28

You have reached the last page of results.This site can display upto 274 results.

Biorxiv : the Preprint Server for Biology|February 26, 2024

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapyOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.

Cell Reports. Medicine|June 27, 2025

Overcoming resistance to immunotherapy by targeting CD38 in human tumor explantsOr-Yam Revach, Angelina M Cicerchia, Ofir Shorer, et al.

Nature|January 12, 2023

Targeting TBK1 to overcome resistance to cancer immunotherapyYi Sun, Or-Yam Revach, Seth Anderson, et al.

Nature|October 4, 2023

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunityChristina K Baumgartner, Hakimeh Ebrahimi-Nik, Arvin Iracheta-Vellve, et al.

Pageof 28